文献速递儿童青少年精神

大规模生物标志物联盟进展与自闭症生物标志物开发路径

Recent Progress of Large-Scale Biomarker Consortia and Paths Forward in Autism Biomarker Development.
PubMed 文献 · Biol Psychiatry · 2026-08-13

本文梳理自闭症生物标志物开发的挑战与进展:行为异质性和依赖临床/照护者报告量表限制了敏感性、客观性与可扩展性。作者按FDA/NIH共识框架界定生物标志物,评估脑电与眼动追踪两类模态及自闭症临床试验生物标志物联盟的成果,指出可临床落地的标志物仍难获得并提出前路。

要点

  • 脑电与眼动追踪是自闭症生物标志物中较成熟的两类测量模态。
  • 自闭症临床试验生物标志物联盟已确立若干候选标志物的可行性、稳定性与监管相关性。
  • 可临床落地的自闭症生物标志物仍未实现,需借助分层与多模态数据驱动策略。

核心结论

  • 尽管与自闭症相关的生物学因素在可重复性上已有实质进展,可临床落地的生物标志物仍然难以获得。

研究设计与样本

  • 本文为综述,归纳大规模生物标志物联盟的近期进展,并按美国FDA/NIH共识框架界定生物标志物。
  • 重点评估脑电与眼动追踪两种测量模态,并总结自闭症临床试验生物标志物联盟的研究发现。

主要发现

  • 自闭症因行为异质性及依赖临床医生与照护者报告量表,在敏感性、客观性和可扩展性上存在限制。
  • 生物标志物可提供具生物学基础、标准化且可能更敏感的孤独症表型指标。
  • 自闭症临床试验生物标志物联盟已确立若干候选生物标志物的可行性、稳定性与监管相关性。

关键数值与推荐

  • 文中未报告具体数值、比例、阈值或统计量。

临床怎么用

  • 可关注脑电与眼动追踪候选标志物在临床试验中的可行性、稳定性与监管相关性。
  • 推动生物标志物与生物学界定的行为构念对齐,并拓展至运动与前庭领域。
  • 采用数据驱动、多模态与数字表型方法提升自闭症临床试验就绪度。

局限性

  • 可临床落地的自闭症生物标志物仍未实现,现有进展尚不足以直接用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autism presents significant challenges for clinical research and biomarker development due to behavioral heterogeneity and reliance on clinician- and caregiver-report measures that are limited in sensitivity, objectivity, and scalability. Biomarkers offer a complementary approach by providing biologically grounded, standardized, and potentially more sensitive indicators of the autism phenotype. We outline the potential advantages of biomarkers over traditional clinical assessments, operationalize biomarkers using U.S. Food and Drug Administration/National Institutes of Health consensus frameworks, and evaluate recent progress from large-scale biomarker consortia and the remaining challenges for 2 well-developed measurement modalities: electroencephalography and eye-tracking. We summarize findings from one of these recent biomarker consortia, the Autism Biomarkers Consortium for Clinical Trials, which has established the feasibility, stability, and regulatory relevance of several candidate biomarkers. Despite meaningful advances in the reproducibility of biological factors associated with autism, clinically actionable biomarkers remain elusive. We describe potential paths forward to overcome this obstacle, including leveraging neurogenetic syndromes and genomic stratification, aligning biomarkers with biologically specified behavioral constructs, expanding measurement into motor and vestibular domains, and applying data-driven, multimodal, and digital phenotyping approaches to advance clinical trial readiness in autism.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Griffin JW, Cairney B, Carson WE, et al. Recent Progress of Large-Scale Biomarker Consortia and Paths Forward in Autism Biomarker Development. Biol Psychiatry. 2026. PMID: 42595244. doi:10.1016/j.biopsych.2026.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。